Amneal Lines Up Ready-To-Use Pemetrexed Hybrid
Q1 2024 Launch Planned After FDA Approval For Pemrydi 505(b)(2) Oncology Injectable
Amneal has set a launch date for its ready-to-use presentation of pemetrexed after the FDA approved the 505(b)(2) product under the name of Pemrydi.
